Checkpoint Spikes as Cancer Drug Undergoes FDA Review
Lake Street Remains a Buy on Checkpoint Therapeutics (CKPT)
Checkpoint Therapeutics Shares Rise After FDA Accepts Resubmission of Cosibelimab
Express News | Checkpoint Therapeutics Inc: FDA Has Set a Pdufa Goal Date of December 28, 2024
Express News | Checkpoint Therapeutics Announces FDA Acceptance of Bla Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma
Checkpoint Therapeutics Price Target Maintained With a $34.00/Share by HC Wainwright & Co.
Analysts' Top Healthcare Picks: Checkpoint Therapeutics (CKPT), Mediwound (MDWD)
Checkpoint Therapeutics, GC Cell Collaborate on Cancer Research; Shares Rise
Checkpoint, GC Cell to Evaluate Combo Cancer Therapy
Express News | GC Cell And Checkpoint Therapeutics To Explore Combined Therapeutic Potential Of Cosibelimab
Checkpoint Therapeutics (CKPT.US) has submitted its application for the marketing of PD-L1 targeted antibodies to the US FDA.
According to the SmartFinance APP, Checkpoint Therapeutics (CKPT.US) recently announced that it has resubmitted its biological product license application (BLA) for the PD-L1 targeted antibody Cosibelimab to the United States FDA for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) patients who are not suitable for radical surgery or radiotherapy. Data shows that Cosibelimab is a potential differentiated, high-affinity, fully human IgG1 subtype monoclonal antibody that directly binds with PD-L1 to block P.
Lake Street Sticks to Its Buy Rating for Checkpoint Therapeutics (CKPT)
Express News | Checkpoint Therapeutics Announces $12 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules
Express News | Checkpoint Therapeutics Announces Biologics License Application Resubmission for Cosibelimab
Express News | Checkpoint Therapeutics Shares Are Trading Higher After the Company Announced It Reached Alignment With the FDA on Its on Its Biologics License Application Resubmission Strategy for Cosibelimab
Checkpoint Therapeutics Plans to Resubmit Application for Cancer Treatment Candidate
Lake Street Maintains Checkpoint Therapeutics(CKPT.US) With Buy Rating
Express News | Checkpoint Therapeutics Reaches Alignment With FDA On Its Upcoming Cosibelimab BLA Resubmission
Express News | Checkpoint: To Move Forward With Mid-Year Bla Resubmission Seeking U.S. Marketing Approval for Cosibelimab
Express News | Checkpoint Therapeutics Announces Alignment With FDA Enabling Upcoming Cosibelimab Bla Resubmission
No Data